Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Beat AML Master Trial: novel precision medicine approach in AML

Amy Burd • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia
Beat AML

Amy Burd, PhD, Leukemia and Lymphoma Society, White Plains, NY, discusses the results of the Beat AML master trial (NCT03013998). This study was designed to assess the possibility of using genetic profiling to assign older patients with previously untreated acute myeloid leukemia (AML) to molecularly defined, subtype-specific therapies. Data from this study support the use of precision medicine, patients with AML who elected for treatment assignment based upon cytogenetic and molecular alterations had significantly improved overall survival when compared with those who elected for standard of care treatment. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Amy Burd

1:16
An insight into the Beat AML trial and the value of precision medicine
Amy Burd • 10 Dec 2022
0:56
Patient-reported outcomes explored in the Beat AML trial
Amy Burd • 10 Dec 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals